Government of Zimbabwe has begun rolling out the long-acting HIV prevention injection Lenacapavir in Bulawayo, marking a major step forward in strengthening the national HIV and AIDS response.
The programme, which commenced on Monday following last week’s national launch, is targeting eligible patients from priority and higher-risk groups. Health officials confirmed that beneficiaries are undergoing medical screening to ensure they are suitable for the new injection.
Authorities described the introduction of the long-acting injectable as a significant milestone, noting its potential to ease the burden of daily medication while offering a more discreet and sustainable HIV prevention option.
Acting Bulawayo Provincial Medical Director, Shirley Takaza, said the development marks meaningful progress in Zimbabwe’s ongoing efforts to curb new infections.
“Today we are launching the rollout of the HIV injectable drug. This is a huge milestone and represents a significant step towards enhancing the fight against HIV,” she said.
Members of priority populations welcomed the intervention, saying it would strengthen protection for individuals whose day-to-day circumstances make consistent adherence to daily medication difficult.
Sexual health and HIV/AIDS research expert Byron Chingombe said the injectable represents a breakthrough in prevention efforts.
“This groundbreaking injection reduces pill burden. It is also discreet and self-empowering,” he noted.
Zimbabwe continues to record notable progress in reducing new HIV infections and HIV-related deaths, according to health authorities, who see the introduction of long-acting options as a key addition to the country’s prevention toolbox.
